2018
DOI: 10.1016/j.ejps.2018.03.026
|View full text |Cite
|
Sign up to set email alerts
|

High resolution mass spectrometry-based methodologies for identification of Etravirine bioactivation to reactive metabolites: In vitro and in vivo approaches

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 11 publications
(12 citation statements)
references
References 33 publications
0
12
0
Order By: Relevance
“…Samples from the metabolic stability assay were analyzed by LC-MS using the experimental conditions previously described [36]. The in vitro depletion half-life of 7s, t1/2, was calculated using Equation 1, assuming that the compound follows a first-order kinetic trend (see SI Figure S2).…”
Section: Half-life T1/2 Determinationmentioning
confidence: 99%
See 1 more Smart Citation
“…Samples from the metabolic stability assay were analyzed by LC-MS using the experimental conditions previously described [36]. The in vitro depletion half-life of 7s, t1/2, was calculated using Equation 1, assuming that the compound follows a first-order kinetic trend (see SI Figure S2).…”
Section: Half-life T1/2 Determinationmentioning
confidence: 99%
“…The 60 min aliquot was analyzed by LC-HRMS/MS, as previously described [36]. All spectra corresponding to metabolites were then manually checked.…”
Section: Metabolite Identificationmentioning
confidence: 99%
“…The fragmentation of etravirine is somewhat difficult to understand, because widely different MS–MS spectra have been reported (cf. [ 14 , 58 ]) and accurate- m/z data for etravirine itself were not found; they were only given for the metabolites [ 65 ]. Etravirine ([M+H] + with m/z 435) shows product ions with m/z 144.056 ([C 8 H 5 N 3 ] + ), that is the protonated (4-cyanophenyl)cyanamide, the odd-electron ion with m/z 288.996 ([C 11 H 8 BrN 5 ] +• ) due to the loss of the (4-cyano-2,6-dimethylphenyl)oxidanyl radical (C 9 H 8 NO • ), the ion with m/z 162.950 ([C 3 H 4 BrN 2 O] + ), the ion with m/z 305.998 ([C 11 H 9 BrN 5 O] + ) due to the loss of C 9 H 7 N, and the ion with m/z 303.983 ([C 11 H 7 BrN 5 O] + ) due to the loss of C 9 H 9 N ( Fig.…”
Section: Non-nucleoside Reverse Transcriptase Inhibitors (Nnrtis)mentioning
confidence: 99%
“…2 ). This interpretation is based on metabolism studies [ 65 , 66 ]. The observation of the product ion with m/z 304 for the [D 8 ]-labelled analogue (with labels on the 4-cyano-2,6-dimethylphenyl moiety) [ 67 ] and for the [ 13 C 6 ]-labelled analogues (with labels at the phenyl ring in the 4-cyanophenyl moiety) [ 21 ] also supports part of the interpretation.…”
Section: Non-nucleoside Reverse Transcriptase Inhibitors (Nnrtis)mentioning
confidence: 99%
“…However, lack of information limits researchers’ understanding of the pharmacokinetic behavior of trepibutone. The study of drug metabolism plays a pivotal role in the drug discovery process (Ezzeldin et al, 2017;Godinho et al, 2018;Shankar et al, 2018), which is necessary to explore the metabolic fate thoroughly. The information regarding case reports associated with biotransformation and identification of metabolites will provide researchers with a better understanding about the activity and risks of trepibutone (Huskey et al, 2016; Iegre et al, 2016; Aras et al, 2017; Glaenzel et al, 2018; He and Wan, 2018; Mizuno et al, 2018).…”
Section: Introductionmentioning
confidence: 99%